Literature DB >> 1310010

Dual regulation of cyclic AMP formation by thrombin in HEL cells, a leukaemic cell line with megakaryocytic properties.

L F Brass1, M J Woolkalis.   

Abstract

Thrombin is thought to stimulate responsive cells by cleaving cell-surface receptors coupled to intracellular second-messenger-generating enzymes via G-proteins. In order to understand this process better, we have examined the regulation of adenylate cyclase by thrombin in the megakaryoblastic HEL cell line and compared it with platelets. A notable difference was found. In HEL-cell membrane preparations, thrombin inhibited cyclic AMP (cAMP) formation by a pertussis-toxin-sensitive mechanism comparable with that observed in platelets. In contrast, when added to intact HEL cells, thrombin activated adenylate cyclase and caused an increase in cAMP formation synergistic with that produced by forskolin and prostaglandin I2. This increase, which was not seen with platelets, was accompanied by an increase in cAMP metabolism by phosphodiesterase. Like other responses to thrombin, the increase in cAMP formation required proteolytically active thrombin and was subject to homologous desensitization. An equivalent response could be evoked by the addition of a polypeptide, derived from the N-terminus of the thrombin receptor, that has been shown to activate the receptor. The effects of thrombin could not, however, be reproduced by the addition of phorbol ester and the Ca2+ ionophore, A23187, nor be prevented with inhibitors of arachidonate metabolism. Preincubation of the cells with adrenaline, which inhibited Gs-mediated activation of adenylate cyclase, or pertussis toxin, which inhibited phospholipase C activation, had no effect on thrombin-induced cAMP formation. These results suggest that thrombin can regulate cAMP formation by two different mechanisms. First, thrombin can inhibit adenylate cyclase in a Gi-dependent manner. This effect predominates in HEL-cell membrane preparations, as it does in platelets, but is not detectable when thrombin is added to intact HEL cells. Instead, in intact HEL cells thrombin activates adenylate cyclase. Although clearly receptor-mediated, this response does not appear to involve Gi, Gs, protein kinase C, eicosanoid formation or changes in the cytosolic Ca2+ concentration.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310010      PMCID: PMC1130642          DOI: 10.1042/bj2810073

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Identification of the pertussis toxin-sensitive G proteins in platelets, megakaryocytes, and human erythroleukemia cells.

Authors:  A G Williams; M J Woolkalis; M Poncz; D R Manning; A M Gewirtz; L F Brass
Journal:  Blood       Date:  1990-08-15       Impact factor: 22.113

2.  Identification of Gz alpha as a pertussis toxin-insensitive G protein in human platelets and megakaryocytes.

Authors:  A W Gagnon; D R Manning; L Catani; A Gewirtz; M Poncz; L F Brass
Journal:  Blood       Date:  1991-09-01       Impact factor: 22.113

3.  Structure of the platelet membrane glycoprotein IIb. Homology to the alpha subunits of the vitronectin and fibronectin membrane receptors.

Authors:  M Poncz; R Eisman; R Heidenreich; S M Silver; G Vilaire; S Surrey; E Schwartz; J S Bennett
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

4.  GTP gamma S increases thrombin-mediated inositol trisphosphate accumulation in permeabilized human endothelial cells.

Authors:  T A Brock; E L Capasso
Journal:  Am Rev Respir Dis       Date:  1989-10

5.  Adenylyl cyclase amino acid sequence: possible channel- or transporter-like structure.

Authors:  J Krupinski; F Coussen; H A Bakalyar; W J Tang; P G Feinstein; K Orth; C Slaughter; R R Reed; A G Gilman
Journal:  Science       Date:  1989-06-30       Impact factor: 47.728

6.  PADGEM protein in human erythroleukemia cells.

Authors:  E Yeo; B C Furie; B Furie
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

7.  Activation of protein kinase C modulates the adenylate cyclase effector system of B-lymphocytes.

Authors:  E Wiener; A Scarpa
Journal:  J Biol Chem       Date:  1989-03-15       Impact factor: 5.157

8.  Thrombin and trypsin act at the same site to stimulate phosphoinositide hydrolysis and calcium mobilization.

Authors:  L G Jones; P M McDonough; J H Brown
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

9.  Inhibition by forskolin of cytosolic calcium rise, shape change and aggregation in quin2-loaded human platelets.

Authors:  S O Sage; T J Rink
Journal:  FEBS Lett       Date:  1985-08-19       Impact factor: 4.124

10.  Structure of platelet glycoprotein IIIa. A common subunit for two different membrane receptors.

Authors:  A B Zimrin; R Eisman; G Vilaire; E Schwartz; J S Bennett; M Poncz
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

View more
  4 in total

1.  Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway.

Authors:  Lily I Jiang; Julie Collins; Richard Davis; Keng-Mean Lin; Dianne DeCamp; Tamara Roach; Robert Hsueh; Robert A Rebres; Elliott M Ross; Ronald Taussig; Iain Fraser; Paul C Sternweis
Journal:  J Biol Chem       Date:  2007-02-05       Impact factor: 5.157

2.  Regulation of cAMP responses by the G12/13 pathway converges on adenylyl cyclase VII.

Authors:  Lily I Jiang; Julie Collins; Richard Davis; Iain D Fraser; Paul C Sternweis
Journal:  J Biol Chem       Date:  2008-06-09       Impact factor: 5.157

3.  Crosstalk between thrombin and adenylyl cyclase-stimulating agonists in proliferating human erythroid progenitor cells.

Authors:  H Porzig; R Gutknecht; K Thalmeier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

Review 4.  Harnessing the platelet signaling network to produce an optimal hemostatic response.

Authors:  Lawrence F Brass; Maurizio Tomaiuolo; Timothy J Stalker
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-11       Impact factor: 3.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.